HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
Huagongshe Open Program:[email protected]AI access: llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.7.8
  1. Home
  2. /Compound

Eberconazole

HCID 72051
NotesReactions
Basic informationOverviewNames & identifiersPropertiesChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
128326-82-9
Standard SMILES
Clc1cc(Cl)c2c(c1)CCc1ccccc1C2n1ccnc1
InChIKey
MPTJIDOGFUQSQH-UHFFFAOYSA-N
Molecular formula
C18H14Cl2N2
Average molar mass
329.2 g/mol
Monoisotopic mass
328.0534038

Overview

1-(2,4-dichloro-10,11-dihydrodibenzo[a,d][7]annulen-5-yl)imidazole is a member of the class of dibenzannulenes that is 10,11-dihydrodibenzo[a,d][7]annulene carrying two chloro substituents at positions 2 and 4 as well as an imidazol-1-yl substituent at position 5. It is a member of imidazoles, a dibenzannulene and an organochlorine compound. It derives from a hydride of a dibenzo[a,d][7]annulene.

Names & identifiers

Preferred name
Eberconazole
IUPAC
1-(4,6-dichloro-2-tricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,11,13-hexaenyl)imidazole
English name
Eberconazole
Molecular formula
C18H14Cl2N2
Molecular weight
329.22

Names & synonyms

Eberconazole128326-82-9EberconazolEberconazolumV7O1U41C9BDTXSID909261041-(2,4-dichloro-10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-yl)-1H-imidazoleRefChem:920795CHEBI:82862D01AC17DTXCID6013549231-(4,6-dichlorotricyclo(9.4.0.0^(3,8))pentadeca-1(15),3,5,7,11,13-hexaen-2-yl)-1H-imidazole
Show more names
1H-Imidazole, 1-(2,4-dichloro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-(+/-)-1-(2,4-Dichloro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)imidazole
Eberconazole [INN]1-(4,6-dichloro-2-tricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,11,13-hexaenyl)imidazole1-(2,4-dichloro-10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-yl)-1H-imidazoleEberconazole (INN)Eberconazol [INN-Spanish]Eberconazolum [INN-Latin]UNII-V7O1U41C9BWAS-2160

Database identifiers

CAS
128326-82-9
PubChem CID
72051
DTXSID
DTXSID90926104

Properties

Computed structural properties

XLogP
4.9
Topological polar surface area
17.8 Ų
Hydrogen bond donors
0
Hydrogen bond acceptors
1
Rotatable bonds
1
Heavy atoms
22
Formal charge
0
Complexity
391

Physicochemical properties

Boiling point
495 · 495.0±45.0 °C(Predicted)
Density
1.35 · 1.35±0.1 g/cm3(Predicted)
pka
5.84 · 5.84±0.10(Predicted)
FDA UNII
7 O1U41C9B · V7O1U41C9B
ATC code
1 AC17 · D01AC17

Chemistry & industry

Pharmacology

ATC Code · 2 items

D - Dermatologicals

QD - Dermatologicals

PharmacodynamicsEberconazole is active against Gram-positive bacteria, dermatophytes, and yeasts.
Mechanism of ActionEberconazole shares a mechanism of action with other antimycotic azoles: It inhibits lanosterol 14a-demethylase, thereby blocking the synthesis of precursors of ergosterols.
Applications · 2 items

DescriptionEberconazole is a new member of the azole class of antifungal agents, and it is indicated for the topical treatment of cutaneous fungal infections, including tinea corporis (ringworm of the body), tinea cruris (ringworm of the groin) and tinea pedis (athlete’s foot) infections. Its mode of action is similar to that of other azole antifungals, namely inhibition of fungal lanosterol 14α-demethylase. Eberconazole exhibits good in vitro activity against a wide range of Candida species, including Candida. tropicalis, dermatophytes and Malassezia spp. yeasts. It shows good activity against Candida. Parapsilosis (MIC90=0.125 mg/mL), which is a relevant species in skin and nail disorders. In addition, eberconazole is effective against some of the highly triazole-resistant yeasts such as Candida. glabrata and Candida. krusei, as well as fluconazole-resistant Candida. albicans. However, eberconazole is less active than clotrimazole and ketoconazole against Candida. neoformans and a number of clinically relevant molds. Eberconazole is supplied as a 1% or 2% cream, and the topical application does not result in detectable serum, urine, or fecal levels. In a phase II study of 60 patients with tinea corporis and tinea cruris, treatment with topical eberconazole (1% or 2% cream), applied once or twice daily for 6 weeks, resulted in cure rates ranging from 73.3–93.3% at the end of therapy, and 66.7–100% six weeks post-therapy.

UsesEberconazole can be used for a novel antifungal formulation.

Suppliers9 total

Related reactions

0 records
New reaction record

No reaction records under the current filter.

Compound notes

Loading…

On this pageBasic informationOverviewNames & identifiersPropertiesChemistry & industryRelated reactionsCompound notes
ChEMBL
CHEMBL558722
ChEBI
CHEBI:83584
UNII
V7O1U41C9B
Nikkaji
J561.862B
深圳市思美泉生物科技有限公司17683743113;18038040196 · [email protected]
深圳振强药物研发有限公司+86-0755-66853366 +86-13670046396 · [email protected]
BOC Sciences16314854226; +8616314854226 · [email protected]
天津康利欣科技有限公司18622939839 · [email protected]
上海陶术生物科技股份有限公司13564774135 · [email protected]
TargetMol中国(陶术生物)4008200310 15002144251 · [email protected]
重庆卡兰医药有限公司[email protected]
DAYANG CHEM (HANGZHOU) CO.,LTD+86-88938639 +86-17705817739 · [email protected]
湖北清北云研医药科技有限责任公司18162595016; 18162595016 · [email protected]
Additional notes · 1 item

DefinitionChEBI: 1-(2,4-dichloro-10,11-dihydrodibenzo[a,d][7]annulen-5-yl)imidazole is a member of the class of dibenzannulenes that is 10,11-dihydrodibenzo[a,d][7]annulene carrying two chloro substituents at positions 2 and 4 as well as an imidazol-1-yl substituent at position 5. It is a member of imidazoles, an organochlorine compound and a dibenzannulene. It derives from a hydride of a dibenzo[a,d][7]annulene.